Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Lupin Limited (LUPIN.NS)

Compare
1,927.30
-85.50
(-4.25%)
At close: 3:09:02 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Ms. Vinita D. Gupta CEO & Executive Director 235.59M -- 1968
Mr. Ramesh Swaminathan Executive Director, Global CFO, CRO & Head of API Plus SBU 73.61M -- 1965
Mr. Nilesh Deshbandhu Gupta MD & Executive Director 95.78M -- 1974
Mr. Christoph Funke Chief Technical Operations Officer -- -- --
Mr. Sreeji Gopinathan Chief Information Officer -- -- --
Dr. Shahin Fesharaki President -Global Chief Scientific Officer -- -- --
Mr. Ravi Agrawal Sr. Vice President of Investor Relations and M&A -- -- --
Dr. Sofia Mumtaz President of Legal and Compliance of Australia, Japan & Canada Business -- -- --
Mr. Amit Kumar Gupta Company Secretary & Compliance Officer -- -- --
Ms. Rajalakshmi Azariah Vice President & Global Head of Corporate Communications -- -- --

Lupin Limited

Kalpataru Inspire
3rd Floor Off. Western Expressway Highway Santacruz (East)
Mumbai, 400055
India
91 22 6640 2323 https://www.lupin.com
Sector: 
Healthcare
Full Time Employees: 
19,210

Description

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Corporate Governance

Lupin Limited’s ISS Governance QualityScore as of April 1, 2025 is 3. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 1; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC

Lupin Limited Earnings Date

Recent Events

July 16, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers